OncoMatch/Clinical Trials/NCT06859424
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Is NCT06859424 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for aml (acute myelogenous leukemia).
Treatment: Conditioning Regimen A · Conditioning Regimen B · Conditioning Regimen C · Conditioning Regimen D · Conditioning Regimen E · PTCy (50 mg/kg D3, D4) · PTCy (25 mg/kg D3, D4) · Post-transplant Tacrolimus · Post-transplant Mycophenolate mofetil · Post-transplant Abatacept · Post-transplant Ruxolitinib · Supportive Care: Growth Factors · Supportive Care: Seizure prophylaxis · Supportive Care: Prophylaxis against infections — The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: allogeneic transplant
Subjects with a prior allogeneic transplant
Cannot have received: autologous transplant
Exception: autologous transplant within the past 3 months
Subjects with an autologous transplant within the past 3 months
Lab requirements
Kidney function
Estimated creatinine clearance ≥ 45mL/min calculated by equation
Liver function
Liver function acceptable per local institutional guidelines
Cardiac function
Left ventricular ejection fraction ≥ 45% (MAC) or ≥ 40% (RIC/NMA) based on most recent echocardiogram or MUGA results
Cardiac function: Left ventricular ejection fraction ≥ 45% (MAC) or ≥ 40% (RIC/NMA); Estimated creatinine clearance ≥ 45mL/min; Liver function acceptable per local institutional guidelines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- City of Hope · Duarte, California
- Stanford · Palo Alto, California
- University of Miami · Miami, Florida
- University of Kansas Medical Center · Westwood, Kansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify